Palmitoyl Tetrapeptide-7 vs Survodutide
Side-by-side comparison of key properties, dosing, and research.
Skin & Cosmetic
Palmitoyl Tetrapeptide-7GLP-1 / Weight Loss Agonists
Survodutide- Summary
- Palmitoyl Tetrapeptide-7 (Rigin) is a cosmetic peptide consisting of palmitic acid linked to the tetrapeptide sequence GQPR (Gly-Gln-Pro-Arg). It was designed to mimic the biological activity of the IgG immunoglobulin C-terminus, which downregulates the production of interleukin-6 (IL-6), a key driver of skin aging and inflammation.
- Survodutide is a once-weekly GLP-1/glucagon dual receptor agonist developed by Boehringer Ingelheim and Zealand Pharma. Phase 2 trials demonstrated up to 18.7% body weight reduction at 46 weeks, among the highest reported for a dual agonist. It is being studied for obesity and MASH (metabolic dysfunction-associated steatohepatitis), where the glucagon component drives hepatic fat clearance.
- Half-Life
- Topical penetration-dependent; effects last hours to days
- ~7 days
- Admin Route
- Topical
- SubQ
- Research
- —
- —
- Typical Dose
- 2-5 ppm concentration in formulation
- 0.6 mg → 2.4 mg → 4.8 mg → 6 mg
- Frequency
- Twice daily
- Once weekly
- Key Benefits
- Reduces IL-6 inflammatory cytokine in skin
- Prevents 'inflammaging' of the skin
- Inhibits MMP collagen-degrading enzymes
- Synergistic with Matrixyl for anti-aging
- Clinically tested for wrinkle and skin texture improvement
- Well-tolerated topically
- Up to 18.7% body weight reduction at 46 weeks (Phase 2)
- Strong MASH activity — Phase 3 SYNCHRONIZE-NASH trials ongoing
- Reduces hepatic fat content via glucagon receptor-driven liver oxidation
- Once-weekly subcutaneous injection
- Greater weight loss potential than GLP-1 monotherapy
- Improvements in liver fibrosis markers in early data
- Side Effects
- Contact sensitization (rare)
- Well-tolerated at standard concentrations
- Nausea (most common during titration)
- Vomiting
- Diarrhea
- Decreased appetite
- +3 more
- Stacks With
- —
- —